COL3A1 and brain neoplasm: Given that SOX2 is a key transcription factor in normal stem cells including pluripotent and tissue-specific stem cells41 and that it has been shown to be expressed in brain tumours and other cancers42, it is possible that the up-regulation of COL3A1 and SOX2 expressions may contribute to the development of resistance to tranilast treatment.